Both Exelixis Inc. (NASDAQ:EXEL) and Aptinyx Inc. (NASDAQ:APTX) are Biotechnology companies, competing one another. We will contrast their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.
Valuation and Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis Inc. 853.83M 7.54 690.07M 1.18 18.13 Aptinyx Inc. 6.72M 29.91 46.41M -1.42 0.00 Table 1 highlights Exelixis Inc. and Aptinyx Inc.’s top-line revenue, earnings per share (EPS) and valuation.
Table 2 provides us the net margins, return on equity and return on assets of both companies. Exelixis Inc. 80.82% 55.7% 43.8% Liquidity
Exelixis Inc. has a Current Ratio of 8.7 and a Quick Ratio of 8.5. Competitively, Aptinyx Inc.’s Current Ratio is 21.8 and has 21.8 Quick Ratio. Aptinyx Inc.’s better ability to pay short and long-term obligations than Exelixis Inc.
Recommendations and Ratings for Exelixis Inc. and Aptinyx Inc. can be find in next table.
Exelixis Inc.’s downside potential is -4.74% at a $20.5 consensus price target.
Institutional and Insider Ownership
Institutional investors owned 79.2% of Exelixis Inc. shares and 76% of Aptinyx Inc. shares. About 0.9% of Exelixis Inc.’s share are owned by insiders. On the other hand, insiders owned about 3.9% of Aptinyx Inc.’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders. Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD) Exelixis Inc. 5.17% 23.4% 13.62% 11.66% -20.59% -29.74% Aptinyx Inc. -6.03% -19.01% -34.47% 0% 0% 3.32% For the past year Exelixis Inc. has -29.74% weaker performance while Aptinyx Inc. has 3.32% stronger performance.
Exelixis Inc. beats Aptinyx Inc. on 9 of the 12 factors.
Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The companyÂ’s products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder. The company has a collaboration agreement with Allergan plc. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.
Click here to view original web page at Exelixis Inc. (EXEL) and Aptinyx Inc. (NASDAQ:APTX) Contrasting side by side